Possible clinical cure of metastatic breast cancer: Lessons from our 30-year experience with oligometastatic breast cancer patients and literature review

Breast Cancer

Volumn 19, Issue 3, 2012, Pages 218-237

  Kobayashi, Tadashi ^a   Ichiba, Tamotsu ^a   Sakuyama, Toshikazu ^a   Arakawa, Yasuhiro ^a   Nagasaki, Eijiroh ^a   Aiba, Keisuke ^a   Nogi, Hiroko ^a   Kawase, Kazumi ^a   Takeyama, Hiroshi ^a   Toriumi, Yasuo ^a   Uchida, Ken ^a   Kobayashi, Masao ^a   Kanehira, Chihiro ^a   Suzuki, Masafumi ^a   Ando, Naomi ^b   Natori, Kazuhiko ^c   Kuraishi, Yasunobu ^c  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JIKEI UNIVERSITY HOSPITAL   (Japan)

^c TOHO UNIVERSITY OMORI MEDICAL CENTER   (Japan)

Author keywords

Clinical cure; Cure; Metastatic breast cancer; Oligometastatic breast cancer; Relapse free survival

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; KI 67 ANTIGEN; METHOTREXATE; MITOMYCIN C; PROGESTERONE RECEPTOR; TEGAFUR; VINCRISTINE;

ADULT; AGED; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MULTIMODALITY CANCER THERAPY; OLIGOMETASTATIC BREAST CANCER; ORGAN SIZE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIMARY TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR VOLUME; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; GUIDELINES AS TOPIC; HUMANS; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84866418462     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/s12282-012-0347-0     Document Type: Review

References (53)

1. Tan S-H, Wolff AC. Treatment of metastatic breast cancer: chemotherapy. In: Harris JR, Lippman ME, Morrow M, Osborne CK, editors. Diseases of the breast. 4th ed. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins; 2010. p. 877-919.
2. Pagani O, Senkus E, Wood W, Colleoni M, Cufer T, Kyriakides S, et al. International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured? J Natl Cancer Inst. 2010;102:456-63.
3. Hayes DF. General principles of management of metastatic breast cancer. Up To Date. 2010; version 18.3.
4. Hortobagyi GN. Can we cure limited metastatic breast cancer? J Clin Oncol. 2002;20:620-3. (Pubitemid 34111365)
5. Guarneri V, Conte PF. The curability of breast cancer and the treatment of advanced disease. Eur J Nucl Med Mol Imaging. 2004;31:S149-61. (Pubitemid 38833045)
6. Greenberg PA, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol. 1996;14:2197-205. (Pubitemid 26264869)
7. Giordano SH, Buzdar AU, Smith TL, Kau SW, Yang Y, Hortobagyi GN. Is breast cancer survival improving? Cancer. 2004;100:44-52.
8. Chia SK, Speers CH, D'yachkova Y, Kang A, Malfair-Taylor S, Barnett J, et al. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer. 2007;110:973-9. (Pubitemid 47312861)
9. Mauri D, Polyzos NP, Salanti G, Pavlidis N, Ioannidis JP. Multiple- treatments meta-analysis of chemotherapy and targeted therapies in advanced breast cancer. J Natl Cancer Inst. 2008;100:1780-91.
10. Fentiman IS, Cuzick J, Millis RR, Hayward JL. Which patients are cured of breast cancer? Br Med J (Clin Res Ed). 1984;289:1108-11. (Pubitemid 15201223)
11. Güth U, Huang DJ, Dirnhofer S, Rochlitz C, Wight E. Distant metastatic breast cancer as an incurable disease: a tenet with a need for revision. Cancer J. 2009;15:81-6.
12. Wood WC. Breast surgery in advanced breast cancer: local control in the presence of metastases. Breast. 2007;16:S63-6.
13. Burstein HJ, Harris JR, Morrow M. Malignant tumors of the breast. In: DeVita VT Jr, Lawrence TS, Rosenberg SA (eds) Cancer, 8th ed. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins; 2008. p. 1606-54.
14. Swenerton KD, Legha SS, Smith T, Hortobagyi GN, Gehan EA, Yap HY, et al. Prognostic factors in metastatic breast cancer treated with combination chemotherapy. Cancer Res. 1979;39:1552-62. (Pubitemid 9172673)
15. Rahman ZU, Frye DK, Smith TL, Asmar L, Theriault RL, Buzdar AU, et al. Results and long term follow-up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin- containing chemotherapy. Cancer. 1999;85:104-11. (Pubitemid 29031363)
16. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13:8-10.
17. Hanrahan EO, Broglio KR, Buzdar AU, Theriault RL, Valero V, Cristofanilli M, et al. Combined-modality treatment for isolated recurrences of breast carcinoma: update on 30 years of experience at the University of Texas M.D. Anderson Cancer Center and assessment of prognostic factors. Cancer. 2005;104:1158-71. (Pubitemid 41278950)
18. Hortobagyi GN. Treatment of breast cancer. N Engl J Med. 1998;339:974-84. (Pubitemid 28455101)
19. WHO Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication No. 48, Geneva: WHO; 1979.
20. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205-16. (Pubitemid 30099779)
21. Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009;101:736-50.
22. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med. 2009;360:790-800.
23. Tomiak E, Piccart M, Mignolet F, Sahmoud T, Paridaens R, Nooy M, et al. Characterisation of complete responders to combination chemotherapy for advanced breast cancer: a retrospective EORTC Breast Group study. Eur J Cancer. 1996;32A: 1876-87. (Pubitemid 26361679)
24. Babiera GV. Metastatic breast cancer: a paradigm shift toward a more aggressive approach. Cancer J. 2009;15:78.
25. Halsted WS. The results of operations for the cure of cancer of the breast performed at the Johns Hopkins Hospital from June, 1889, to January, 1894. Ann Surg. 1894;20:497-555.
26. Halsted WS. The results of radical operations for the cure of carcinoma of the breast. Ann Surg. 1907;46:1-19.
27. Fisher B. Laboratory and clinical research in breast cancer-a personal adventure: the David A. Karnofsky memorial lecture. Cancer Res. 1980;40:3863-74. (Pubitemid 11234057)
28. Hellman S. Natural history of small breast cancers. J Clin Oncol. 1994;12:2229-34. (Pubitemid 24356043)
29. Skipper HE, Schabel FM Jr, Wilcox WS. Experimental evaluation of potential anticancer agents XIII. On the criteria and kinetics associated with "curability" of experimental leukemia. Cancer Chemother Rep. 1964;35:1-111.
30. Goldie JH, Coldman AJ. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep. 1979;63:1727-33. (Pubitemid 10138923)
31. Norton L. Conceptual and practical implications of breast tissue geometry: toward a more effective, less toxic therapy. Oncologist. 2005;10:370-81. (Pubitemid 40993565)
32. Cristofanilli M, Broglio KR, Guarneri V, Jackson S, Fritsche HA, Islam R, et al. Circulating tumor cells in metastatic breast cancer: biologic staging beyond tumor burden. Clin Breast Cancer. 2007;7:471-9. (Pubitemid 46424284)
33. Borner M, Bacchi M, Goldhirsch A, Greiner R, Harder F, Castiglione M, et al. First isolated locoregional recurrence following mastectomy for breast cancer: results of a phase III multicenter study comparing systemic treatment with observation after excision and radiation. J Clin Oncol. 1994;12:2071-7. (Pubitemid 24356023)
34. Blumenschein GR, DiStefano A, Caderao J, Fristenberg B, Adams J, Schweichler LH, et al. Multimodality therapy for locally advanced and limited stage IV breast cancer: the impact of effective non-cross-resistance late-consolidation chemotherapy. Clin Cancer Res. 1997;3:2633-7. (Pubitemid 28133119)
35. Nieto Y, Nawaz S, Jones RB, Shpall EJ, Cagnoni PJ, McSweeney PA, et al. Prognostic model for relapse after high-dose chemotherapy with autologous stem-cell transplantation for stage IV oligometastatic breast cancer. J Clin Oncol. 2002;20:707-18. (Pubitemid 34111378)
36. Rivera E, Holmes FA, Buzdar AU, Asmar L, Kau SW, Fraschini G, et al. Fluorouracil, doxorubicin, and cyclophosphamide followed by tamoxifen as adjuvant treatment for patients with stage IV breast cancer with no evidence of disease. Breast J. 2002;8:2-9. (Pubitemid 34118477)
37. Rauschecker H, Clarke M, Gatzemeier W, Recht A Systemic therapy for treating locoregional recurrence in women with breast cancer. The Cochrane Library. 2008; (Issue 4). Review. doi:10.1002/14651858.CD002195
38. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology-Breast Cancer Version 2. 2011. http://www.nccn.com. Accessed 2 Aug 2011.
39. Cady B, Nathan NR, Michaelson JS, Golshan M, Smith BL Matched pair analyses of stage IV breast cancer with or without resection of primary breast site. Ann Surg Oncol. 2008;15:3384-95
40. Wapnir IL, Aebi S, Geyer CE, Zahrieh D, Gelber RD, Anderson SJ, et al. A randomized clinical trial of adjuvant chemotherapy for radically resected locoregional relapse of breast cancer: IBCSG 27-02, BIG 1-02, and NSABP B-37. Clin Breast Cancer. 2008;8:287-92. (Pubitemid 351962153)
41. Metastatic breast cancer. Recommendations proposal from the European School of Oncology (ESO)-MBC Task Force. Breast. 2007;16:9-10.
42. Wolff AC. Systemic therapy. Curr Opin Oncol. 2002;14:600-8. (Pubitemid 35387369)
43. Hryniuk WM, Levine MN, Levin L. Analysis of dose intensity for chemotherapy in early (stage II) and advanced breast cancer. NCI Monogr. 1986;1:87-94. (Pubitemid 17200850)
44. The French Adjuvant Study Group. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year followup results of French Adjuvant Study Group 05 randomized trial. J Clin Oncol. 2001;19:602-11.
45. Wood WC, Budman DR, Korzun AH, Cooper MR, Younger J, Hart RD, et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med. 1994;330:1253-9.
46. Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003;21:976-83. (Pubitemid 46594124)
47. Yanada M, Garcia-Manero G, Borthakur G, Ravandi F, Kantarjian H, Estey E. Potential cure of acute myeloid leukemia: analysis of 1069 consecutive patients in first complete remission. Cancer. 2007;110:2756-60. (Pubitemid 350250346)
48. Estey E, Döhner H. Acute myeloid leukaemia. Lancet. 2006;368:1894-907. (Pubitemid 44794525)
49. Tallman MS, Gilliland DG, Rowe JM. Drug therapy for acute myeloid leukemia. Blood. 2005;106:1154-63. (Pubitemid 41130866)
50. Crosby WH. To treat or not to treat acute granulocytic leukemia. Arch Intern Med. 1968;122:79-80.
51. Boggs DR, Wintrobe MM, Cartwright GE. To treat or not to treat acute granulocytic leukemia. II. Arch Intern Med. 1969;123:568-70.
52. Crosby WH. Grounds for optimism in treating acute granulocytic leukemia. Arch Intern Med. 1974;134:177-80.
53. Yamamoto N, Katsumata N, Watanabe T, Omuro Y, Ando M, Narabayashi M, et al. Clinical characteristics of patients with metastatic breast cancer with complete remission following systemic treatment. Jpn J Clin Oncol. 1998;28:368-73. (Pubitemid 128522966)